US FDA Urged To Improve Messaging To Professional Societies On Accelerated Approval Withdrawals
Executive Summary
Lengthy withdrawal process creates an opening for the FDA to better convey its concerns about a medicine’s benefit-risk profile in a way that impacts prescribing guidelines, Johns Hopkins’ Joshua Sharfstein says; CDER’s Jacqueline Corrigan-Curay says new expedited withdrawal procedures under omnibus law appear more ‘streamlined’ than those followed for Makena.
You may also be interested in...
Accelerated Approval: US FDA Should Explain Why An Ongoing Trial Is Not Required
Having a confirmatory trial underway at the time of approval should be the ‘default expectation’ and the agency should publicly explain when and why it grants exceptions to this rule, experts said at a National Academies meeting on accelerated approval.
FDA One Step Closer To Makena Withdrawal After Hearing Officer Echoes Advisory Panel’s Advice
In a memo to Commissioner Califf and Chief Scientist Bumpus, Celia Witten focuses the final Makena decisionmakers on the key factors she believes should be used to determine the drug’s market status.
Makena’s Reimbursement Coverage Remained Unchanged After Confirmatory Trial Failure
As milestone approaches in FDA effort to pull the pre-term birth drug, the findings suggest that by leaving Makena on the market, the agency may be ‘furthering plan inaction,’ Tufts Medical Center researchers conclude.